Head and neck squamous cell carcinoma, thyroid carcinoma
Conditions
Brief summary
qualitative count of lesions with significant [¹⁸F]AlF-PSMA-11 uptake on PET. For each subject, all endpoints are measured within 12 months after the last trial-specific intervention (trial-specific PET/CT or blood sampling) for that subject (LTIS). For the whole trial, all endpoints are measured within 12 months after the overall last trial-specific intervention (LTI), that is, after the last of all LTISs. (analyse PET images and blood and tissue samples until 12 months after the overall LTISs)
Detailed description
semiquantitative lesion radiotracer [¹⁸F]AlF-PSMA-11 uptake values on PET. For each subject, all endpoints are measured within 12 months after LTIS. For the whole trial, all endpoints are measured within 12 months after LTI.(analyse PET images and blood and tissue samples until 12 months after the overall LTISs), semiquantitative organ-level radiotracer [¹⁸F]AlF-PSMA-11 uptake values on PET. For each subject, all endpoints are measured within 12 months after LTIS. For the whole trial, all endpoints are measured within 12 months after LTI.(analyse PET images and blood and tissue samples until 12 months after the overall LTISs)
Interventions
DRUG[18F]PSMA-11
Sponsors
Universitair Ziekenhuis Gent
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| qualitative count of lesions with significant [¹⁸F]AlF-PSMA-11 uptake on PET. For each subject, all endpoints are measured within 12 months after the last trial-specific intervention (trial-specific PET/CT or blood sampling) for that subject (LTIS). For the whole trial, all endpoints are measured within 12 months after the overall last trial-specific intervention (LTI), that is, after the last of all LTISs. (analyse PET images and blood and tissue samples until 12 months after the overall LTISs) | — |
Secondary
| Measure | Time frame |
|---|---|
| semiquantitative lesion radiotracer [¹⁸F]AlF-PSMA-11 uptake values on PET. For each subject, all endpoints are measured within 12 months after LTIS. For the whole trial, all endpoints are measured within 12 months after LTI.(analyse PET images and blood and tissue samples until 12 months after the overall LTISs), semiquantitative organ-level radiotracer [¹⁸F]AlF-PSMA-11 uptake values on PET. For each subject, all endpoints are measured within 12 months after LTIS. For the whole trial, all endpoints are measured within 12 months after LTI.(analyse PET images and blood and tissue samples until 12 months after the overall LTISs) | — |
Countries
Belgium
Outcome results
None listed